quinoxalines has been researched along with Liver Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Capelletti, MM; Manceau, H; Peoc'h, K; Puy, H | 1 |
| Butterton, JR; Caro, L; Fandozzi, C; Feng, HP; Garrett, G; Huang, X; Iwamoto, M; Lasseter, KC; Liu, F; Marbury, T; Marshall, WL; Panebianco, D; Preston, RA; Wenning, L; Yeh, WW | 1 |
| Gane, E; Kort, J; Kosloski, MP; Lawitz, E; Liu, W; Marbury, TC; Mensa, FJ; Preston, RA; Pugatch, D; Wang, H | 1 |
| Asatryan, A; Elkhashab, M; Gane, E; Greenbloom, S; Lin, CW; Liu, W; Mensa, FJ; Mulkay, JP; Nguyen, T; Pilot-Matias, T; Poordad, F; Porcalla, A; Setze, C; Stedman, C; Tran, A; Valdes, J; Wang, S; Wörns, MA; Yu, Y; Zadeikis, N | 1 |
| Franck, AJ; Sliter, LR | 1 |
| Fukushima, S; Kang, JS; Morimura, K; Totsuka, Y; Wanibuchi, H; Yoshimura, I | 1 |
1 review(s) available for quinoxalines and Liver Diseases
| Article | Year |
|---|---|
Ferroptosis in Liver Diseases: An Overview.
Topics: alpha-Tocopherol; Animals; Autophagy; Chemical and Drug Induced Liver Injury; Cyclohexylamines; Cysteine; Ferroptosis; Glutathione; Heme; Humans; Iron; Kelch-Like ECH-Associated Protein 1; Lipid Peroxidation; Lipoxygenase; Liver Diseases; Liver Neoplasms; Oxidative Stress; Phenylenediamines; Phospholipid Hydroperoxide Glutathione Peroxidase; Piperazines; Quinoxalines; Reactive Oxygen Species; Reperfusion Injury; Signal Transduction; Sorafenib; Spiro Compounds; Sulfasalazine; Tumor Suppressor Protein p53 | 2020 |
1 trial(s) available for quinoxalines and Liver Diseases
| Article | Year |
|---|---|
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Liver Diseases; Male; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response | 2019 |
4 other study(ies) available for quinoxalines and Liver Diseases
| Article | Year |
|---|---|
Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment.
Topics: Adult; Aged; Amides; Benzofurans; Carbamates; Cyclopropanes; Female; Humans; Imidazoles; Liver Diseases; Male; Middle Aged; Quinoxalines; Sulfonamides | 2018 |
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.
Topics: Adolescent; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Humans; Lactams, Macrocyclic; Leucine; Liver; Liver Diseases; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2019 |
Acute hepatic injury associated with varenicline in a patient with underlying liver disease.
Topics: Acute Disease; Benzazepines; Hepatitis C; Humans; Liver Diseases; Liver Diseases, Alcoholic; Liver Function Tests; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Varenicline | 2009 |
Existence of a no effect level for MeIQx hepatocarcinogenicity on a background of thioacetamide-induced liver damage in rats.
Topics: 5-Methylcytosine; Animals; Carcinogens; Chemical and Drug Induced Liver Injury; Chromatography, High Pressure Liquid; DNA Adducts; Dose-Response Relationship, Drug; Glutathione Transferase; Immunohistochemistry; Liver Diseases; Liver Neoplasms, Experimental; Male; Quinoxalines; Rats; Thioacetamide | 2006 |